leisure time -WSS

leisure time

author：hotspot 2025-09-06 02:10:59 - browse：919

JOSEPH PREZIOSO/AFP via Getty Images

LONDON — The U.K.’s cost-effectiveness watchdog said Thursday it is not yet recommending Vertex’s CRISPR-based therapy for sickle cell disease, saying in draft guidance it has questions about the medicine’s lasting benefits for patients.

U.K. regulators approved the therapy, known as Casgevy or exa-cel, last year, granting it the world’s first authorization for any CRISPR-based medicine. But observers have been watching to see how the U.K.’s National Institute for Health and Care Excellence, as well as similar agencies in European countries, would view the pricey, one-time therapy. NICE needs to recommend the therapy for it to be offered in the National Health Service.

In the U.S., Casgevy has a list price of $2.2 million. It was developed by Vertex in partnership with CRISPR Therapeutics.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： With psoriasis trial ahead, Alumis raises $259 million

WSS

Change Healthcare cyberattack prompts Medicare loan program

Precocious puberty in girls comes with mental health risks

Mississippi candidates for statewide offices square off in party primaries

Teen said 'homophobic slurs' before O'Shae Sibley killing: Criminal complaint

First medicine developed to treat MASH expected to be approved soon

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

leisure time

leisure time

leisure time

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Democratic lawmaker calls for 'well

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

DeSantis and Newsom agree to Sean Hannity debate, then disagree on the rules

How to save PrEP access — and even expand it

Change Healthcare cyberattack prompts Medicare loan program

Medicare details structure of new drug price negotiation program

Amylyx ALS drug failure raises questions and concerns

United colonoscopy coverage change 'may cost lives,' doctors say

Prince Harry and Meghan to work on film adaptation of 'Meet Me at the Lake' novel

focus

Trump lawyer welcomes Pence testifying in Jan. 6 trial, won't say if Trump will too

Elon Musk says he may need surgery before proposed 'cage match' with Mark Zuckerberg

Just how do doctors, lawmakers, and the public define abortion?

IVF, abortion rights issues kick off Biden’s State of the Union

The Readout: Amylyx, Alumis, and Lundbeck drug updates

Just how do doctors, lawmakers, and the public define abortion?

explore

knowledge

focus

Wikipedia